摘要
摘要：目的 随机对照研究棕榈酸帕利哌酮与利培酮治疗精神分裂症患者有效性与安全性。方法 选择于 2018年 10月～ 2019年 10月在我院治疗的精神分裂症患者 68例作为研究对象，随机分为观察组（ 34例）与对照组（ 34例）。给予对照组利培酮口服治疗，观察组则应用棕榈酸帕利哌酮肌肉注射治疗。分析两组用药治疗的有效性与安全性。结果 治疗前两组阳性和阴性症状量表（ PANSS）评分结果对比，差异无统计学意义（ P>0.05）；治疗后 12 w、 24 w、 36 w及 48 w时观察组 PANSS评分结果优于对照组，差异有统计学意义（ P<0.05）；两组用药治疗期间不良反应发生率对比，差异无统计学意义（ P>0.05）。结论 精神分裂症患者应用棕榈酸帕利哌酮治疗效果更为理想，可有效改善患者精神症状，加速患者康复进程，安全性高，临床普及价值高。 关键词：棕榈酸帕利哌酮；利培酮；精神分裂症；有效性；安全性 Abstract: Objective To study the efficacy and safety of palmitate and risperidone in the treatment of schizophrenia. Methods 68 schizophrenic patients who were treated in our hospital from October 2018 to October 2019 were randomly divided into observation group (34 cases) and control group (34 cases). The control group was given risperidone orally, while the observation group was given palipexone palmitate intramuscular injection. The efficacy and safety of the two groups were analyzed. Results there was no significant difference in PANSS between the two groups before treatment (P > 0.05); the PANSS score of the observation group was better than that of the control group at 12W, 24W, 36W and 48W after treatment (P < 0.05); there was no significant difference in adverse reactions between the two groups during treatment (P > 0.05). Conclusion palmitone palmitate is more effective in the treatment of schizophrenia. It can effectively improve the mental symptoms of patients, accelerate the rehabilitation process of patients, with high safety and high clinical popularization value.
出版日期
2020年04月20日（中国Betway体育网页登陆平台首次上网日期，不代表论文的发表时间）
